



COLLEGE of AMERICAN
PATHOLOGISTS

Laboratory Quality Solutions

Surveys and Anatomic Pathology Education Programs

Performance Improvement Program in Surgical Pathology PIP/PIPW-B 2024

Participant Summary

This document is available online in e-LAB Solutions Suite.

© 2024 College of American Pathologists. The CAP does not permit reproduction of any substantial portion of the material in this Report without its written authorization. The CAP hereby authorizes participants in the program to use the material in this Report solely for educational purposes within their own institutions. The CAP prohibits use of the material in the Report — and any unauthorized use of the CAP's name or logo — in connection with promotional efforts by marketers of laboratory equipment, reagents, materials, or services. Data from this program do not necessarily indicate the superiority or inferiority of instruments, reagents, or other materials used by participating laboratories. Use of these data to suggest such superiority or inferiority may be deceptive and misleading. The CAP will take all steps open to it under the law to prevent unauthorized reproduction of substantial portions of the material in this Report, deceptive use of any such material, and any unauthorized use of the CAP's name or logo in connection with promotional efforts by marketers of laboratory equipment, reagents, materials, or services.

2024 PIP/PIPW-B PARTICIPANT SUMMARY

Program Update

This report summarizes the diagnostic responses for set B of the 2024 Performance Improvement Program in Surgical Pathology (PIP & PIPW).

A tabulation of the responses to the supplementary questions is not included since these are intended for educational purposes only.

SURGICAL PATHOLOGY COMMITTEE

Raul Gonzalez, MD, FCAP, Chair
Vinita Parkash, MBBS, MPH, FCAP, Vice Chair

Nadine S. Aguilera MD, FCAP
Israh Akhtar MD, MBBS, FCAP
John M. Carney MD, FCAP
Bonnie Choy, MD, FCAP
Miriam Conces, MD, FCAP
Katelyn Dannheim MD, FCAP
Kossivi Dantey, MD, FCAP
Patrick Henn MD, BS, FCAP
Juan C. Hernandez-Prera, MD, FCAP
Mojgan Hosseini, MD, FCAP
Aaron Ryan Huber DO, FCAP

Abberly Lott Limbach MD, FCAP
Mitra Mehrad, MD, FCAP
Ekene Okoye MD, FCAP
Anwar Sultana Sabiha Raza, MD, FCAP
Daniel J Reiter MD, FCAP
Nicole D Riddle MD, MSHI, FCAP
Steven S. Shen, MD, PhD, FCAP
Thing Rinda Soong MD, PhD, FCAP
Sara E. Wobker MD, MPH, FCAP
Maximillian Weigelt, MD, (Jr. Member)

Note: Beginning in 2024 the first two cases of the online version of PIP (PIPW- PIP Web version) will not duplicate the first 2 cases in the PIP (Glass slide) program.

The PIPW/PIPW1 programs offer 10 cases with the benefit of slides being provided in an online, whole slide image format, which allows for each clinical case history and respective slide to be presented in a side-by-side format. This allows for inclusion of smaller tumors and biopsies.

Cases W01 and W02 show results from PIPW/PIPW1 participants.

Cases 01 and 02 show results from PIP/PIP1 participants.

Case # 2024-W11	Diagnosis					
	Epithelioid hemangioma					
	Code	Diagnosis	PIP Participants		PIPW Participants	
		No.	%	No.	%	
		Epithelioid angiosarcoma			112	32.6
		Epithelioid hemangioendothelioma			76	22.1
		Epithelioid hemangioma			141	41.0
		Epithelioid sarcoma			15	4.4
		Metastatic melanoma			0	0.0

Case # 2024-W12	Diagnosis					
	Sinonasal undifferentiated carcinoma					
	Code	Diagnosis	PIP Participants		PIPW Participants	
		No.	%	No.	%	
		Diffuse large B-cell lymphoma			2	0.6
		Malignant mucosal melanoma			1	0.3
		Olfactory neuroblastoma			12	3.6
		Sinonasal squamous cell carcinoma non-keratinizing			23	6.9
		Rhabdomyoma			16	4.8
		Sinonasal undifferentiated carcinoma			277	83.7

Case # 2024-11	Diagnosis					
	(5678) Leiomyosarcoma, spindle (conventional) subtype					
	Code	Diagnosis	PIP Participants		PIPW Participants	
		No.	%	No.	%	
		1951 Carcinosarcoma	8	0.1		
		5877 Fumarate hydratase (FH)-deficient uterine leiomyoma	18	0.3		
		1646 Leiomyoma	97	1.8		
		5678 Leiomyosarcoma, spindle (conventional) subtype	5394	97.7		
		2316 Perivascular epithelioid cell tumor (PEComa)	3	<0.1		

Case # 2024-12	Diagnosis					
	(2387) Angiomyolipoma					
	Code	Diagnosis	PIP Participants		PIPW Participants	
		No.	%	No.	%	
		2387 Angiomyolipoma	5519	99.7		
		2056 Hemangioma	0	0.0		
		1646 Leiomyoma	2	<0.1		
		2443 Lipoma	3	0.1		
		2256 Well-differentiated liposarcoma	1	<0.1		

Case # 2024-13

Diagnosis

(2250) Neuroendocrine carcinoma

Code	Diagnosis	PIP Participants		PIPW Participants	
		No.	%	No.	%
2930	Extra-adrenal paraganglioma	21	0.4	12	3.7
5879	Gastric adenocarcinoma	1	<0.1	2	0.6
1901	Gastrointestinal stromal tumor	12	0.2	6	1.9
2389	Leiomyosarcoma	5	0.1	5	1.5
2250	Neuroendocrine carcinoma	5254	95.2	244	75.5
1736	Well-differentiated neuroendocrine tumor, WHO grade 3	221	4.0	54	16.7

Case # 2024-14

Diagnosis

(2383) Seminoma

Code	Diagnosis	PIP Participants		PIPW Participants	
		No.	%	No.	%
2454	Diffuse large B-cell lymphoma	8	0.1	7	2.2
1994	Embryonal carcinoma, solid pattern	9	0.2	11	3.5
2383	Seminoma	5484	99.3	278	87.4
2341	Sertoli cell tumor	7	0.1	6	1.9
5608	Spermatocytic tumor	12	0.2	13	4.1
2863	Yolk sac tumor, solid pattern	5	0.1	3	0.9

Case # 2024-15

Diagnosis

(5880) Extragonadal yolk sac tumor

Code	Diagnosis	PIP Participants		PIPW Participants	
		No.	%	No.	%
5880	Extragonadal yolk sac tumor	5500	99.5	300	95.8
5881	Metastatic ovarian clear cell carcinoma	1	<0.1	1	0.3
5882	Metastatic TFE3-rearranged renal cell carcinoma	0	0.0	1	0.3
2319	Myxopapillary ependymoma	11	0.2	6	1.9
5883	Teratoma with somatic type malignancy	9	0.2	5	1.6

Case # 2024-16

Diagnosis

(5836) Succinate dehydrogenase-deficient renal cell carcinoma

Code	Diagnosis	PIP Participants		PIPW Participants	
		No.	%	No.	%
1984	Chromophobe renal cell carcinoma	19	0.3	12	3.9
1665	Clear cell renal cell carcinoma	16	0.3	3	1.0
5884	Eosinophilic vacuolated tumor	11	0.2	14	4.5
5836	Succinate dehydrogenase-deficient renal cell carcinoma	5465	98.9	277	89.1
5885	TFE3-rearranged renal cell carcinoma	14	0.3	5	1.6

Diagnosis					
(2504) Plexiform neurofibroma					
Code	Diagnosis	PIP Participants		PIPW Participants	
		No.	%	No.	%
2499	Dermatofibrosarcoma protuberans	9	0.2	4	1.3
5562	Malignant peripheral nerve sheath tumor	10	0.2	14	4.5
5795	Perineurioma	51	0.9	18	5.8
2504	Plexiform neurofibroma	5408	98.0	258	83.0
1206	Plexiform schwannoma	39	0.7	17	5.5

Diagnosis					
(5888) Tenosynovial giant cell tumor, localized type					
Code	Diagnosis	PIP Participants		PIPW Participants	
		No.	%	No.	%
1668	Epithelioid sarcoma	7	0.1	4	1.3
5886	Giant cell fibroblastoma	9	0.2	7	2.3
5887	Giant cell tumor of soft tissue	85	1.5	31	10.0
1807	Myoepithelioma	9	0.2	8	2.6
5888	Tenosynovial giant cell tumor, localized type	5403	98.0	261	83.9

Diagnosis					
(2250) Neuroendocrine carcinoma					
Code	Diagnosis	PIP Participants		PIPW Participants	
		No.	%	No.	%
2454	Diffuse large B-cell lymphoma	1	<0.1	1	0.3
2699	Invasive ductal carcinoma	3	0.1	6	1.9
1673	Metaplastic carcinoma	6	0.1	6	1.9
1932	Metastatic small cell lung carcinoma	11	0.2	7	2.3
2250	Neuroendocrine carcinoma	5465	99.0	276	89.0
5889	Solid papillary carcinoma	25	0.5	14	4.5

Diagnosis					
(5890) Drug-related massive hepatic necrosis					
Code	Diagnosis	PIP Participants		PIPW Participants	
		No.	%	No.	%
1008	Cholangiocarcinoma	96	1.7	40	12.9
1872	Cirrhosis	13	0.2	7	2.3
5890	Drug-related massive hepatic necrosis	5347	97.0	247	79.4
5891	Hypoxic ischemic liver injury	43	0.8	10	3.2
1803	Primary biliary cholangitis	15	0.3	7	2.3



This concludes the report.



COLLEGE of AMERICAN
PATHOLOGISTS

Laboratory Quality Solutions

325 Waukegan Road
Northfield, IL 60093-2750
800-323-4040
847-832-7000 (Country code: 1)